Please login to the form below
Webinar: How to develop an optimal value story for your product
This webinar is part of the ongoing expert insights series run by Valid Insight
Thursday 30th July at 2pm BST / 9am EST
Developing a compelling, differentiated, value proposition is crucial for optimal market access. With input from a panel of experts, Raf De Wilde, our Senior Executive Advisor, and Carolyn Steeds, Associate Director, will discuss how to develop a successful payer value strategy while avoiding some of the common pitfalls that experience tells can hinder pricing and market access success.
Expert panelists:
- Marcus Dahlman, European Head of Market Access at Hansa Biopharma.
- Brent Fraser, Vice President of CADTH, Pharmaceutical Reviews.
- Harry Ward, Former director of Commissioning to Wolverhampton City Primary Care Trust
Company Details
Valid Insight
+44 (0) 20 3750 9833
Address:
152-160 City Road
Kemp House
London
EC1V 2NX
United Kingdom
Latest content on this profile
- Valid Insight are hiring for Consultants in Value Communication (mid to senior levels)
- New role available for Consultants in Value Communication with experience in market access writing and value communication.
Valid Insight
- Webinar: Maintaining market access through a pandemic, 6 months on
- In this webinar, Valid Insight explore market access and how it has evolved through a pandemic over the past 6 months.
Valid Insight
- Webinar: How to develop an optimal value story for your product
- This webinar is part of the ongoing expert insights series run by Valid Insight
Valid Insight
- Last chance to register - Webinar: How to price a pharmaceutical product during a global economic recession
- How can you ensure your product achieves optimal market access during a global economic recession?
Valid Insight
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen.
Valid Insight
- Why are new medicinal products denied reimbursement in France?
- Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative to alternative treatments for successful market access. In this blog, we summarise the reasons for negative reimbursement decisions in 2017 and discuss common pitfalls manufacturers should avoid.
Valid Insight
